Clinical analysis of five cases of transcatheter PDA closure intervention for hsPDA in very-low-birth-weight preterm infants
10.3760/cma.j.cn113903-20241127-00789
- VernacularTitle:极低出生体重早产儿合并hsPDA经导管PDA封堵术：５例临床分析
- Author:
Junhui LIU
1
;
Shuai GAO
1
;
Yi SUN
1
;
Gang LUO
1
;
Silin PAN
1
Author Information
1. 青岛大学附属妇女儿童医院心脏中心，青岛 266034
- Publication Type:Journal Article
- Keywords:
Transcatheter intervention;
Patent ductus arteriosus;
Very low birth weight;
Preterm infants
- From:
Chinese Journal of Perinatal Medicine
2025;28(9):755-761
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the characteristics of hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) preterm infants and evaluate the efficacy and safety of transcatheter PDA closure (TCPC).Methods:This was a retrospective study including five VLBW preterm infants who were diagnosed with hsPDA by echocardiography at Women and Children's Hospital, Qingdao University from January to December 2024 and underwent transcatheter closure after pharmacological therapy failure. Follow-up assessments were conducted at 6 months after operation to evaluate PDA closure status, survival outcomes, and the occurrence of complications. Descriptive statistical analysis was used to summarize the demographic characteristics and clinical data.Results:The cohort comprised three males and two females. The median gestational age was 28 (24-29) weeks, and the median birth weight was 1 000 (670-1 220) g. The median age and birth weight at surgery were 25 (13-36) d and 1 200 (810-1 400) g, respectively. The PDA diameter was 3.8 (2.3-4.1) mm. PDA closure was successfully achieved in all five infants using the Amplatzer Piccolo? occlude, with no major procedure-related complications. All patients were weaned from mechanical ventilation and discharged. At 6-month follow-up, all five infants survived with no residual shunt, left pulmonary artery stenosis, or aortic coarctation on echocardiography.Conclusions:TCPC is feasible and safe for VLBW preterm infants when pharmacological therapy is ineffective or contraindicated. Larger cohorts and extended follow-up are needed to assess long-term outcomes and potential complications.
